poisar

Stocks · News reference

GSK Plans To Stop Further Development Of Camlipixant In Refractory Chronic Cough As Camlipixant 25mg Twice Daily Failed To Meet Statistical Significance In CALM-1, CALM-2 Clinical Trials

BenzingaJul 17, 2026, 11:44 AMBenzinga Newsdesk

https://www.gsk.com/en-gb/media/press-releases/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials/

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 17, 2026, 11:44 AM
Checked
Jul 17, 2026, 11:44 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading